Background Tumor necrosis factor (TNF) antagonists are highly effective for the treatment of rheumatoid arthritis (RA), but their mechanisms of action are not completely clear. Increased expression of CD147 on monocytes/macrophages in RA may be responsible for elevated MMP secretion and cell invasion, which may contribute to the cartilage and bone destruction of RA.
Objectives To investigate the effects of TNF-inhibitor (infliximab) on CD147 expression and MMP-3 level in patients with rheumatoid arthritis.
Methods 15 patients with active rheumatoid arthritis received intravenous infliximab at a dose of 3mg/kg at weeks 0, 2, 6, 14, and 22, in combination with methotrexate. Patient's disease activity was assessed by the Disease Activity Score (DAS28). Peripheral blood mononuclear cells (PBMCs) and serum samples were collected at weeks 0, 14, and 26.Concentrations of MMP-3 was determined by enzyme-linked immunosorbent assays; CD147 expression on CD14+ monocytes was detected by flow cymetory.
Results DAS28 score showed improvement at weeks 14 and 26 than the baseline (0 week) after inliximab treatment. The mean fluorescence intensity (MFI) of CD147 expression on CD14+ monocytes of peripheral blood from RA patients decreased at 14 week and 26 week. Serum MMP-3 level also decreased significantly after the treatment. The correlation analysis showed that the DAS28 was correlated with CD147 expression on CD14+ cells in PB of RA and the serum level of MMP-3. When the patients were grouped on the basis of their clinical response to infliximab, a significant decrease in CD147 and MMP-3 was observed in patients who had clinical improvement.
Conclusions Anti-TNF treatment in rheumatoid arthritis results in a decrease in CD147 expression and the serum level of MMP-3 in patients showing clinical improvement, indicating the efficacy of TNF inhibitory treatment of RA is associated with CD147 and MMP-3 and that these measurements may be a useful adjunct in assessing treatment efficacy.
Disclosure of Interest None declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.